Company / Net Income
Jazz Pharmaceuticals Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$356.1M
FY2025
5-year range
-$356.1M / $560.1M
FY2021-FY2025
Trend
-163.6%
vs FY2024
Sector context
#187 of 216
Health Care
What the data says
Jazz Pharmaceuticals's net income of -$356M is lower than 87% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$356M in FY2025 to $560M in FY2024.
Based on SEC 10-K filings.
-$356M in FY2025.
Declined from $415M to -$356M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 216This company -$356.1M Sector average $454.1M
▼
-178.4% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 163.6% year-over-year.
- Ranks #187 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$356.1M | -163.6% |
| FY2024 | $560.1M | +35.0% |
| FY2023 | $414.8M | +73.8% |
| FY2022 | $238.6M | -54.4% |
| FY2021 | $523.4M | +17.1% |
| FY2020 | $447.1M | -8.4% |
| FY2019 | $487.8M | +22.9% |
| FY2018 | $396.8M | -18.7% |
| FY2017 | $487.8M | +735.5% |
| FY2016 | $58.4M | -82.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026